Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.60EUR
22 Jul 2016
Change (% chg)

€0.38 (+0.50%)
Prev Close
€76.22
Open
€76.20
Day's High
€77.00
Day's Low
€75.90
Volume
1,713,816
Avg. Vol
2,787,523
52-wk High
€101.10
52-wk Low
€62.50

Latest Key Developments (Source: Significant Developments)

Medivation sets record date for Sanofi's proposed consent solicitation
Wednesday, 1 Jun 2016 06:45pm EDT 

Medivation Inc : Medivation sets record date for Sanofi's proposed consent solicitation . Says accordance with Sanofi's request, company's board of directors has set close of business on June 1, 2016 .In accordance with request, co's board of directors has set close of business on June 1, as record date for Sanofi consent solicitation.  Full Article

Sanofi requests record date for consent solicitation to remove and replace Medivation's board
Wednesday, 1 Jun 2016 02:15pm EDT 

Sanofi SA : Latest day Medivation board can set record date is June 22, 2016 . Sanofi requests record date for consent solicitation to remove and replace Medivation's board of directors .Pursuant to terms of its bylaws, Medivation is required to adopt a resolution fixing record date within 10 calendar days of request.  Full Article

Sanofi expected to request record date from Medivation today - CNBC, citing sources
Wednesday, 1 Jun 2016 09:52am EDT 

: Sanofi expected to request record date from Medivation today- CNBC, citing sources (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780).  Full Article

Parnell Pharmaceuticals says manufacturing deal with Merial
Tuesday, 31 May 2016 04:05pm EDT 

Parnell Pharmaceuticals Holdings Ltd : Parnell Pharmaceuticals Holdings announces contract manufacturing agreement with Merial .Estimates total value of deal between $7 million and $20 million depending on volume of product purchased by Merial over 10-year term.  Full Article

FDA recommends approval of Sanofi treatment for Type 2 Diabetes
Wednesday, 25 May 2016 06:50pm EDT 

Sanofi : FDA advisory committee recommends approval of Sanofi treatment for adults with Type 2 Diabetes . Says both studies met their primary endpoints . "Look forward to continuing to work with FDA as it completes its reviews of these new drug applications" .FDA advisory committee recommends approval of Sanofi treatment for adults with Type 2 Diabetes.  Full Article

Medivation says urges stockholders to reject Sanofi's attempt to replace co's board of directors
Wednesday, 25 May 2016 09:00am EDT 

Medivation Inc : Medivation urges stockholders to reject sanofi's attempt to replace medivation board of directors . Expects to promptly file consent revocation materials with u.s. Securities and exchange commission .Believes sanofi's attempt to replace board is a "tactic for sanofi to facilitate" its proposal to acquire medivation.  Full Article

Sanofi sends letter to Medivation board of directors
Wednesday, 25 May 2016 08:43am EDT 

Sanofi : Sanofi files consent solicitation to remove and replace Medivation's board . Today sent letter to the Medivation board of directors . Sanofi to Medication board - "Request that you engage in good faith with Sanofi as part of a sale process" . Sanofi to Medication board - "If you" engage in good faith, "we would not need to proceed" with consent solicitation to replace Medivation directors Further company coverage: [SASY.PA] ((Bengaluru Newsroom; +1 646 223 8780;)).  Full Article

Sanofi seeking shareholder support for removal of Medivation board
Wednesday, 25 May 2016 06:25am EDT 

Sanofi : Sanofi says seeking shareholder support for removal of board as of time removal proposal becomes effective and election of nominees . Soliciting consents from medivation shareholders to take actions including 8 directors elected by board before proposal effectiveness is removed . Sending consent statement to medivation shareholders to put in place board that co believes will evaluate options, including offer to buy medivation . Sanofi says if nominees are elected to medivation's board, intend to continue to pursue acquisition proposal . Soliciting consents from medivation shareholders to take actions including its 8 nominees be elected to serve as director of the company . Sanofi will pay all costs of the solicitation and will not seek reimbursement of those costs from medivation . Sanofi is asking medivation shareholders to consent to : bylaw restoration proposal, board vacancy proposal,removal proposal,election proposal . Sanofi's nominees for medivation board include michael campbell, barbara deptula, wendy lane, ronald rolfe, steven shulman, charles slacik .Sanofi's nominees for medivation board also include james tyree and david wilson.  Full Article

Sanofi says Pascale Witz, executive VP, diabetes & cardiovascular, to leave company on June 1
Monday, 23 May 2016 08:19am EDT 

Sanofi : Sanofi announces changes to executive committee aligned to its strategic roadmap 2020 . Pascale witz, executive vice president, diabetes & cardiovascular, will leave company on june 1 . Suresh kumar, executive vice president, external affairs, has decided to return to united states for personal reasons . Plans to name at a later date an executive vice president, consumer healthcare who will be a member of executive committee . Olivier brandicourt will serve as acting head of external affairs until a replacement is found to succeed suresh kumar .Suresh has agreed to continue to represent sanofi's interest in u.s. Until year-end.  Full Article

ALK-Abello names Carsten Hellmann new CEO
Wednesday, 18 May 2016 12:59am EDT 

ALK-Abello A/S : Said on Tuesday Board of Directors had appointed Carsten Hellmann as new President and Chief Executive . Hellmann is currently CEO of Merial and Executive Vice President and member of the Executive Committee of Sanofi .Hellmann to take up CEO position no later than Jan. 1, 2017.  Full Article

BRIEF-Sanofi Enzyme says Ontario adds LEMTRADA to exceptional access program for eligible patients

* Ontario adds Lemtrada (Alemtuzumab) to exceptional access program for eligible patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)